Using aspirin for cancer prevention

Assessing biosimilars in the real world setting

Effective communication about biosimilars

Practical guidance on the assessment of biosimilar monoclonal antibodies: A pharmacist's perspective

Realising the potential of biosimilars

Comment: Supporting a sustainable biosimilar solution

Comment: CDK4/6 inhibitors in advanced breast cancer

Ovarian highlights from ESMO 2019

Comment: Osimertinib for EGFR-mutation positive NSCLC

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Regulatory principles for biosimilar medicines

Impact of cancer prevention campaigns in Brazil: A google trends analysis